Understanding how MYC gene activation affects diffuse large B-cell lymphoma
Identifying Functional Drivers of MYC Activation via Developmental Enhancers in Diffuse Large B-cell Lymphoma
This study is looking at how a gene called MYC behaves in a type of cancer called diffuse large B-cell lymphoma (DLBCL) to find new ways to improve treatments and help doctors predict how the disease will progress for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10880680 on NIH RePORTER |
What this research studies
This research investigates the role of the MYC oncogene in diffuse large B-cell lymphoma (DLBCL), a type of cancer that affects B cells. The team aims to uncover how MYC is activated through specific genetic enhancers, particularly in cases where MYC does not have typical genomic rearrangements. By using advanced techniques like CRISPR interference, they will identify the essential regulatory elements that control MYC expression. The ultimate goal is to develop better treatment strategies and predictive biomarkers for patients with DLBCL.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-risk diffuse large B-cell lymphoma, particularly those without MYC genomic rearrangements.
Not a fit: Patients with other types of lymphoma or those whose DLBCL is not high-risk may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and personalized therapies for patients with diffuse large B-cell lymphoma.
How similar studies have performed: Previous research has shown promising results in targeting oncogene regulation in various cancers, suggesting potential success for this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Ryan, Russell James Hubbard — University of Michigan at Ann Arbor
- Study coordinator: Ryan, Russell James Hubbard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.